Table 1.
Patients’ characteristics at baseline and treatment response.
Characteristics | No. of patients(N = 151) | Percentage(%) |
---|---|---|
Age(years), median(IQR) | 63(54-69) | |
≥ 63 | 81 | 53.6 |
< 63 | 70 | 46.4 |
Gender | ||
Female | 36 | 23.8 |
Male | 115 | 76.2 |
Tumor histology | ||
Squamous | 50 | 33.1 |
Non-Squamous | 101 | 66.9 |
Adenocarcinoma | 92 | 60.9 |
Others† | 9 | 6.0 |
Stage | ||
Recurrence | 29 | 19.2 |
Advanced | 122 | 80.8 |
IIIB | 29 | 19.2 |
IV | 93 | 61.6 |
ECOG PS | ||
0-1 | 147 | 97.4 |
2 | 4 | 2.6 |
Smoking history | ||
Never | 60 | 39.7 |
Now/ever | 91 | 60.3 |
No. of metastasis sites | ||
0 | 32 | 21.2 |
1 | 72 | 47.4 |
2 | 33 | 21.9 |
≥ 3 | 14 | 9.3 |
Mutation type‡ | ||
EGFR | 28 | 18.5 |
KRAS | 7 | 4.6 |
Wild-type | 116 | 76.8 |
Degree of differentiation | ||
Low | 116 | 76 |
Moderate/high | 35 | 23.2 |
PD-1 inhibitor type | ||
Pembrolizumab | 70 | 46.4 |
Sintilimab | 66 | 43.7 |
Toripalimab | 15 | 9.9 |
Combination regimen | ||
Chemotherapy | 105 | 69.5 |
Anti-angiogenic therapy | 18 | 11.9 |
Both | 28 | 18.5 |
Lines of therapy | ||
1 | 61 | 40.4 |
2 | 49 | 32.5 |
≥ 3 | 41 | 27.2 |
Radiotherapy | ||
No | 85 | 56.3 |
Yes | 66 | 43.7 |
Best response | ||
CR | 0 | 0.0 |
PR | 46 | 30.5 |
SD | 88 | 58.3 |
PD | 17 | 11.3 |
†adenosquamouscarcinoma(n = 3), Sarcomatoid carcinoma(n = 2), otherwise(n = 4).
‡ALK mutation(n = 0).
ECOG, Eastern Cooperative Oncology Group; PS, performance status.